Bank of America’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.98M | Buy |
1,378,915
+93,953
| +7% | +$475K | ﹤0.01% | 3037 |
|
|
2025
Q1 | $6.8M | Buy |
1,284,962
+402,098
| +46% | +$2.13M | ﹤0.01% | 2979 |
|
|
2024
Q4 | $5.97M | Sell |
882,864
-282,561
| -24% | -$1.91M | ﹤0.01% | 2890 |
|
|
2024
Q3 | $7.68M | Sell |
1,165,425
-676,040
| -37% | -$4.46M | ﹤0.01% | 2836 |
|
|
2024
Q2 | $13.8M | Buy |
1,841,465
+138,551
| +8% | +$1.04M | ﹤0.01% | 2281 |
|
|
2024
Q1 | $17M | Buy |
1,702,914
+917,637
| +117% | +$9.15M | ﹤0.01% | 2116 |
|
|
2023
Q4 | $7.74M | Sell |
785,277
-113,483
| -13% | -$1.12M | ﹤0.01% | 2639 |
|
|
2023
Q3 | $6.88M | Buy |
898,760
+668,042
| +290% | +$5.11M | ﹤0.01% | 2616 |
|
|
2023
Q2 | $1.72M | Sell |
230,718
-326,292
| -59% | -$2.44M | ﹤0.01% | 3650 |
|
|
2023
Q1 | $3.72M | Buy |
557,010
+135,146
| +32% | +$901K | ﹤0.01% | 3245 |
|
|
2022
Q4 | $3.25M | Buy |
421,864
+222,998
| +112% | +$1.72M | ﹤0.01% | 3266 |
|
|
2022
Q3 | $2.12M | Buy |
198,866
+92,649
| +87% | +$986K | ﹤0.01% | 3604 |
|
|
2022
Q2 | $864K | Buy |
106,217
+22,537
| +27% | +$183K | ﹤0.01% | 4365 |
|
|
2022
Q1 | $599K | Sell |
83,680
-87,495
| -51% | -$626K | ﹤0.01% | 4997 |
|
|
2021
Q4 | $2.93M | Buy |
171,175
+144,668
| +546% | +$2.48M | ﹤0.01% | 3587 |
|
|
2021
Q3 | $610K | Buy |
26,507
+18,630
| +237% | +$429K | ﹤0.01% | 4709 |
|
|
2021
Q2 | $288K | Buy |
+7,877
| New | +$288K | ﹤0.01% | 5080 |
|